Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026

The AGM approved, amongst other items:

• The Annual Report and the Remuneration Report
• The remuneration of the members of the Board of Directors
• The appointment of Mr. Henry Gosebruch as Executive Director
• The appointments of Dr. Jane Griffiths, Ms. Dawn Svoronos, Dr. Neil Johnston, Dr. Paulo Fontoura, and Mr. Gino Santini as Independent Non-Executive Directors and Mr. Devang Bhuva as Non-Executive Director
• The re-appointment of the statutory auditor
• The charging of the statutory auditor with respect to the “assurance” of the CSRD sustainability reporting

The EGM approved, amongst other items:

• The change of the name of the Company to “Lakefront Biotherapeutics”, effective as of May 8, 2026
• The authorization to the Board of Directors to acquire its own shares
• The renewal of the Company’s authorized capital by up to 20% of the share capital
  

All documents related to the AGM and EGM can be consulted on our website. The minutes of the meetings will be made available in due course.

“I am grateful for our shareholder support as we execute our transformation. I would also like to sincerely thank Jérôme for his leadership throughout this transformative period for Galapagos. His guidance and steadfast support through the strategic review and implementation of the Company’s reinvention have been instrumental in positioning Galapagos for its next phase of growth and value creation. He has been a great partner and provided valuable insights,” said Henry Gosebruch, Chief Executive Officer of Galapagos.

Gosebruch continued, “We are delighted to welcome Gino to our Board of Directors as our next Chair. His extensive operational, strategic and business development expertise shaped by global leadership in our sector will be invaluable as we execute on our strategy to deliver meaningful patient impact and sustainable shareholder returns.”

About Galapagos

Galapagos is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Galapagos prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit www.glpg.com or follow us on LinkedIn or X.